Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228033 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Supplemental Calcium in Preventing Postpartum Depression
A Phase 4 study of Depression and Depression, Postpartum, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 238
- Enrollment target
- 1
- Study location
NCT00228033: Completed Phase 4 study of Depression and Depression, Postpartum, sponsored by Oregon Health and Science University.
NCT00228033 is a Phase 4 study of Depression and Depression, Postpartum that has completed, run by Oregon Health and Science University. The registered enrollment target is 238 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00228033, a Phase 4 study of Depression and Depression, Postpartum, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 238 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of taking supplemental calcium while pregnant in reducing the risk of postpartum depression.
Conditions Studied
Interventions
- DRUG Elemental calcium (as carbonate)
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2002-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
What the finished NCT00228033 record still lists
NCT00228033 is an interventional study that assigns participants to a tested intervention. The registered 238 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Elemental calcium (as carbonate) is the first listed.
NCT00228033 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00228033 about?
NCT00228033 is a clinical study titled "Effectiveness of Supplemental Calcium in Preventing Postpartum Depression". This study will evaluate the effectiveness of taking supplemental calcium while pregnant in reducing the risk of postpartum depression.
What is the current status of trial NCT00228033?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 238 participants. The study started on 2002-04. Estimated completion is 2007-08.
What conditions does trial NCT00228033 study?
This clinical trial studies the following conditions: Depression, Depression, Postpartum.
What interventions are being tested in trial NCT00228033?
The interventions under investigation include: Elemental calcium (as carbonate) (DRUG).
Who is sponsoring clinical trial NCT00228033?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00228033 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00228033's enrollment target sits among peer trials
238 187th of 679 higher than 493 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
- NCT06452797 · 238 participants · NA
Prognostic Estimates Among ICU Clinicians
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia